SCHEMBL616694

SCHEMBL616694

Oc1ccc(C2CCOC2)c(O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
TYR P14679 5/20 0.37
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP19A1 P11511 1/20 0.37
RAB9A P51151 2/20 0.36
CYP3A4 P08684 2/20 0.36
NPC1 O15118 2/20 0.36
HSP90AA1 P07900 1/20 0.36
TTR P02766 1/20 0.36
PTPN1 P18031 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 2/20 0.35
ALOX12 P18054 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615733 0.90 PDE3B (0.36) TYRPTGS1PTGS2CYP19A1RAB9A
SCHEMBL614735 0.89 PIK3CD (0.42) PIK3CDPIK3CATYRPTGS1PTGS2
SCHEMBL29429338 0.89 PIK3CD (0.42) PIK3CDPIK3CATYRPTGS1PTGS2
SCHEMBL19249421 0.78 TYR (0.48) TYRPTGS1PTGS2CYP19A1RAB9A
SCHEMBL3162433 0.75 ALDH1A1 (0.43) TYRRAB9ACYP3A4HSP90AA1CHRNB2
SCHEMBL29871375 0.75 ALDH1A1 (0.43) TYRRAB9ACYP3A4HSP90AA1CHRNB2
SCHEMBL614972 0.73 ALDH1A1 (0.38) TYRPTGS1PTGS2CYP19A1RAB9A
SCHEMBL614595 0.73 ALDH1A1 (0.38) TYRPTGS1PTGS2CYP19A1RAB9A
SCHEMBL614596 0.73 ALDH1A1 (0.38) TYRPTGS1PTGS2CYP19A1RAB9A
SCHEMBL21051323 0.73 ESR2 (0.50) CYP3A4TTRALOX12CYP2C9ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016102400-A1 COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102399-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102398-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL L'OREAL (FR) 2016-06-30 WO claimed
WO-2016102402-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL L'OREAL (FR) 2016-06-30 WO claimed
EP-2529735-B1 COMPOSITIONS COMPRISING 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL DERIVATIVES WITH TYROSINASE ENZYME INHIBITING ACTIVITY GALDERMA RES & DEV (FR) 2014-06-25 EP claimed
US-8372879-B2 4-(heterocycloalkyl) benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-02-12 US claimed
EP-2529735-A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics Galderma Research & Development (FR) 2012-12-05 EP claimed
EP-2373310-B1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RES & DEV (FR) 2012-10-10 EP claimed
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-16 US claimed
EP-2373310-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS Galderma Research & Development (FR) 2011-10-12 EP claimed
WO-2010063773-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 WO claimed
WO-2016102400-A1 COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A SPECIFIC SOLVENT L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102399-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND AND A HYDROTROPE L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102398-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A POLYMER AND A GLYCOL L'OREAL (FR) 2016-06-30 WO disclosed
WO-2016102402-A1 AQUEOUS COMPOSITION COMPRISING A 4-(HETEROCYCLOALKYL)-BENZENE-1,3-DIOL COMPOUND, A C2-C4 MONOALCOHOL, AND A GLYCOL L'OREAL (FR) 2016-06-30 WO disclosed
EP-2529735-A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics Galderma Research & Development (FR) 2012-12-05 EP disclosed
EP-2373310-B1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RES & DEV (FR) 2012-10-10 EP disclosed
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-16 US disclosed
EP-2373310-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS Galderma Research & Development (FR) 2011-10-12 EP disclosed
WO-2010063773-A1 NOVEL 4-(HETEROCYCLOALKYL)BENZENE-1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041213-A1 4-(HETEROCYCLOALKYL) BENZENE -1,3-DIOL COMPOUNDS AS TYROSINASE INHIBITORS, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND ALSO IN COSMETICS TYR, DDT, PAH PIK3CD 979/4885PIK3CA 671/4885TYR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.